New insights in uremic toxicity

Contributions to Nephrology

Volumn 149, Issue , 2005, Pages 315-324

  Vanholder, R ^a   Glorieux, G ^a   Lameire, N ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; DINUCLEOSIDE PHOSPHATE; GUANIDINE DERIVATIVE; PEPTIDE; PHENYLACETIC ACID; PHENYLACETIC ACID DERIVATIVE; TOXIN;

HUMAN; METABOLISM; PROTEIN BINDING; REVIEW; UREMIA;

DINUCLEOSIDE PHOSPHATES; GLYCOSYLATION END PRODUCTS, ADVANCED; GUANIDINES; HUMANS; PEPTIDES; PHENYLACETATES; PROTEIN BINDING; TOXINS, BIOLOGICAL; UREMIA;

EID: 20544465914     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000085693     Document Type: Review

References (31)

1. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunei P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W: Review on uremic toxins: Classification, concentration, and interindividual variability. Kidney Int 2003;63:1934-1943.
2. De Deyn PP, D'Hooge R, Van Bogaert PP, Marescau B: Endogenous guanidino compounds as uremic neurotoxins. Kidney Int Suppl 2001;78:S77-S83.
3. De Deyn PP, Marescau B, Cuykens JJ, Van Gorp L, Lowenthal A, De Potter WP: Guanidino compounds in serum and cerebrospinal fluid of non-dialyzed patients with renal insufficiency. Clin Chim Acta 1987;167:81-88.
4. Zoccali C, Benedetto FA, Maas R, Mallamaci F, Tripepi G, Malatino LS, Boger R: Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol 2002;13:490-496.
5. Vallance P, Leone A, Calver A, Collier J, Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-575.
6. Marescau B, Nagels G, Possemiers I, De Broe ME, Becaus I, Billiouw JM, Lornoy W, De Deyn PP: Guanidino compounds in serum and urine of nondialyzed patients with chronic renal insufficiency. Metabolism 1997;46:1024-1031.
7. Glorieux GL, Dhondt AW, Jacobs P, Van Langeraert J, Lameire NH, De Deyn PP, Vanholder RC: In vitro study of the potential role of guanidines in leukocyte functions related to atherogenesis and infection. Kidney Int 2004;65:2184-2192.
8. Ross R: Atherosclerosis - An inflammatory disease. N Engl J Med 1999;340:115-126.
9. Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T: Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999;55:1899-1911.
10. Hirayama A, Noronha-Dutra AA, Gordge MP, Neild GH, Hothersall JS: Inhibition of neutrophil superoxide production by uremic concentrations of guanidino compounds. J Am Soc Nephrol 2000;11:684-689.
11. Perna AF, Ingrosso D, Satta E, Lombardi C, Galletti P, D'Aniello A, De Santo NG: Plasma protein aspartyl damage is increased in hemodialysis patients: Studies on causes and consequences. J Am Soc Nephrol 2004;15:2747-2754.
12. Eloot S, De Smet R, Torremans A, De Wachter D, Marescau B, De Deyn P, Verdonck P, Vanholder R: Urea kinetics are not representative for the behavior of the guanidino compounds. Kidney Int, in press.
13. Vanholder RC, De Smet RV, Ringoir SM: Assessment of urea and other uremic markers for quantification of dialysis efficacy. Clin Chem 1992;38:1429-1436.
14. Miyata T, Wada Y, Cai Z, Iida Y, Horie K, Yasuda Y, Maeda K, Kurokawa K, van Ypersele de Strihou C: Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int 1997;51:1170-1181.
15. Miyata T, Iida Y, Ueda Y, Shinzato T, Seo H, Monnier VM, Maeda K, Wada Y: Monocyte/macrophage response to beta 2-microglobulin modified with advanced glycation end products. Kidney Int 1996;49:538-550.
16. Witko-Sarsat V, Friedlander M, Nguyen KT, Capeillere-Blandin C, Nguyen AT, Canteloup S, Dayer JM, Jungers P, Drueke T, Descamps-Latscha B: Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998;161:2524-2532.
17. Glorieux G, Helling R, Henle T, Brunet P, Deppisch R, Lameire N, Vanholder R: In vitro evidence for immune activating effect of specific AGE structures retained in uremia. Kidney Int 2004;66:1873-1880.
18. Vanholder R, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Massy ZA, Rodriguez M, Stegmayr B, Stenvinkel P, Wratten ML: Uremic toxicity: Present state of the art. Int J Artif Organs 2001;24:695-725.
19. Lesaffer G, De Smet R, Lameire N, Dhondt A, Duym P, Vanholder R: Intradialytic removal of protein-bound uraemic toxins: Role of solute characteristics and of dialyser membrane. Nephrol Dial Transplant 2000;15:50-57.
20. Dou L, Bertrand E, Cerini C, Faure V, Sampol J, Vanholder R, Berland Y, Brunet P: The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int 2004;65:442-451.
21. Cerini C, Dou L, Anfosso F, Sabatier F, Moal V, Glorieux G, de Smet R, Vanholder R, Dignat-George F, Sampol J, Berland Y, Brunet P: P-cresol, a uremic retention solute, alters the endothelial barrier function in vitro. Thromb Haemost 2004;92:140-150.
22. 2+ channels in the neuroexcitatory and synergistic effects of putative uremic neurotoxins. Kidney Int 2003;63:1764-1775.
23. Canalejo A, Almaden Y, De Smet R, Glorieux G, Garfia B, Luque F, Vanholder R, Rodriguez M: Effects of uremic ultrafiltrate on the regulation of the parathyroid cell cycle by calcitriol. Kidney Int 2003;63:732-737.
24. Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y: Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney Int 2003;64:2238-2243.
25. De Smet R, Van Kaer J, Van Vlem B, De Cubber A, Brunet P, Lameire N, Vanholder R: Toxicity of free p-cresol: A prospective and cross-sectional analysis. Clin Chem 2003;49:470-478.
26. Ingrosso D, Cimmino A, Perna AF, Masella L, De Santo NG, De Bonis ML, Vacca M, D'Esposito M, D'Urso M, Galletti P, Zappia V: Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia. Lancet 2003;361:1693-1699.
27. Jankowski J, Luftmann H, Tepel M, Leibfritz D, Zidek W, Schluter H: Characterization of dimethylguanosine, phenylethylamine, and phenylacetic acid as inhibitors of Ca2+ ATPase in end-stage renal failure. J Am Soc Nephrol 1998;9:1249-1257.
28. Jankowski J, van der GM, Jankowski V, Schmidt S, Hemeier M, Mahn B, Giebing G, Tolle M, Luftmann H, Schluter H, Zidek W, Tepel M: Increased plasma phenylacetic acid in patients with end-stage renal failure inhibits iNOS expression. J Clin Invest 2003;112:256-264.
29. Jankowski J, Hagemann J, Yoon MS, van der GM, Stephan N, Zidek W, Schluter H, Tepel M: Increased vascular growth in hemodialysis patients induced by platelet-derived diadenosine polyphosphates. Kidney Int 2001;59:1134-1141.
30. Jankowski V, Tolle M, Vanholder R, Schonfelder G, van der Giet M, Schluter H, Paul M, Zidek W, Jankowski J: Identification of uridine adenosine tetraphosphate (UP4A) as an endothelial-derived vasoconstrictive factor. Nat Med 2005;11:223-227.
31. Weissinger EM, Kaiser T, Meert N, de Smet R, Walden M, Mischak H, Vanholder RC: Proteomics: A novel tool to unravel the patho-physiology of uraemia. Nephrol Dial Transplant 2004;19:3068-3077.